• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    6/3/24 1:35:22 PM ET
    $BIIB
    $COR
    $CORT
    $GPCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Pharmaceuticals
    Health Care
    Get the next $BIIB alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    PHR PUT TRADE NEUTRAL 06/21/24 $20.00 $570.0K 3.2K 3.1K
    LLY CALL SWEEP BEARISH 06/07/24 $850.00 $87.7K 386 1.2K
    CORT PUT SWEEP BEARISH 06/21/24 $30.00 $101.6K 1.4K 660
    GPCR PUT TRADE NEUTRAL 12/19/25 $50.00 $86.6K 0 571
    HIMS CALL SWEEP BULLISH 01/17/25 $20.00 $42.9K 12.6K 436
    NVAX CALL TRADE BULLISH 01/17/25 $20.00 $116.6K 4.2K 418
    COR PUT SWEEP BEARISH 06/21/24 $230.00 $61.2K 134 301
    BIIB CALL SWEEP BULLISH 06/14/24 $230.00 $26.4K 61 157
    VKTX CALL TRADE BULLISH 06/21/24 $60.00 $26.0K 666 121
    HCA PUT SWEEP BULLISH 06/20/25 $330.00 $27.4K 12 78

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • For PHR (NYSE:PHR), we notice a put option trade that happens to be neutral, expiring in 18 day(s) on June 21, 2024. This event was a transfer of 3000 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $570.0K, with a price of $190.0 per contract. There were 3204 open contracts at this strike prior to today, and today 3134 contract(s) were bought and sold.

    • For LLY (NYSE:LLY), we notice a call option sweep that happens to be bearish, expiring in 4 day(s) on June 7, 2024. This event was a transfer of 283 contract(s) at a $850.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $87.7K, with a price of $310.0 per contract. There were 386 open contracts at this strike prior to today, and today 1278 contract(s) were bought and sold.

    • Regarding CORT (NASDAQ:CORT), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on June 21, 2024. Parties traded 654 contract(s) at a $30.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $101.6K, with a price of $160.0 per contract. There were 1416 open contracts at this strike prior to today, and today 660 contract(s) were bought and sold.

    • Regarding GPCR (NASDAQ:GPCR), we observe a put option trade with neutral sentiment. It expires in 564 day(s) on December 19, 2025. Parties traded 85 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $86.6K, with a price of $1020.0 per contract. There were 0 open contracts at this strike prior to today, and today 571 contract(s) were bought and sold.

    • For HIMS (NYSE:HIMS), we notice a call option sweep that happens to be bullish, expiring in 228 day(s) on January 17, 2025. This event was a transfer of 90 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $42.9K, with a price of $478.0 per contract. There were 12652 open contracts at this strike prior to today, and today 436 contract(s) were bought and sold.

    • Regarding NVAX (NASDAQ:NVAX), we observe a call option trade with bullish sentiment. It expires in 228 day(s) on January 17, 2025. Parties traded 299 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $116.6K, with a price of $390.0 per contract. There were 4211 open contracts at this strike prior to today, and today 418 contract(s) were bought and sold.

    • Regarding COR (NYSE:COR), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on June 21, 2024. Parties traded 153 contract(s) at a $230.00 strike. This particular put needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $61.2K, with a price of $400.0 per contract. There were 134 open contracts at this strike prior to today, and today 301 contract(s) were bought and sold.

    • Regarding BIIB (NASDAQ:BIIB), we observe a call option sweep with bullish sentiment. It expires in 11 day(s) on June 14, 2024. Parties traded 44 contract(s) at a $230.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $26.4K, with a price of $600.0 per contract. There were 61 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold.

    • For VKTX (NASDAQ:VKTX), we notice a call option trade that happens to be bullish, expiring in 18 day(s) on June 21, 2024. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $26.0K, with a price of $520.0 per contract. There were 666 open contracts at this strike prior to today, and today 121 contract(s) were bought and sold.

    • For HCA (NYSE:HCA), we notice a put option sweep that happens to be bullish, expiring in 382 day(s) on June 20, 2025. This event was a transfer of 9 contract(s) at a $330.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $3050.0 per contract. There were 12 open contracts at this strike prior to today, and today 78 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BIIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB
    $COR
    $CORT
    $GPCR

    CompanyDatePrice TargetRatingAnalyst
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/9/2026$30.00Hold → Buy
    Needham
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Hims & Hers Health Inc.
    $HIMS
    2/24/2026Buy → Neutral
    BTIG Research
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Biogen Inc.
    $BIIB
    2/20/2026$185.00Equal Weight
    Barclays
    Biogen Inc.
    $BIIB
    2/9/2026$194.00 → $228.00Buy
    H.C. Wainwright
    More analyst ratings

    $BIIB
    $COR
    $CORT
    $GPCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Viking Therapeutics Inc.

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    3/10/26 6:20:39 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CFO and Treasurer Kelly James Patrick converted options into 12,223 shares and covered exercise/tax liability with 5,904 shares, increasing direct ownership by 5% to 130,599 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/9/26 6:13:36 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 4 filed by EVP, CFO and Treasurer Kelly James Patrick

    4/A - NOVAVAX INC (0001000694) (Issuer)

    3/9/26 6:12:20 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Hims & Hers Health from Underperform to Neutral and set a new price target of $23.00

    3/10/26 8:37:14 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by Needham with a new price target

    Needham upgraded Hims & Hers Health from Hold to Buy and set a new price target of $30.00

    3/9/26 11:28:34 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    SEC Filings

    View All

    SEC Form PRE 14A filed by Eli Lilly and Company

    PRE 14A - ELI LILLY & Co (0000059478) (Filer)

    3/6/26 4:35:56 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cencora Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Cencora, Inc. (0001140859) (Filer)

    3/6/26 4:16:32 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Hims & Hers Health Inc.

    SCHEDULE 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    3/5/26 11:49:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Head of Pharm Ops and Tech Murphy Nicole bought $585 worth of shares (3 units at $195.03), increasing direct ownership by 0.02% to 19,611 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/17/26 8:16:40 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BIIB
    $COR
    $CORT
    $GPCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Phreesia Named to the 2026 Capterra Shortlist for Appointment Scheduling

    Phreesia, a leader in patient intake, outreach and activation, has been named to the 2026 Capterra Shortlist for Appointment Scheduling. The Capterra Shortlist is an independent assessment that uses a proprietary blend of user ratings and popularity signals to identify leading products across software categories. Phreesia was named to four Capterra Shortlists in 2025, including for Patient Engagement. "Recognition from Capterra is especially meaningful because it reflects feedback from customers who rely on our solutions," said Phreesia CEO Chaim Indig. "We're proud to support our clients with technology that helps patients schedule care more easily and helps organizations operate more

    3/10/26 4:06:00 PM ET
    $PHR
    Real Estate

    Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers

    The program debuts with Prenuvo and Eight Sleep, providing discounts on advanced diagnostics and sleep technology Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative provides active subscribers access to discounts from health partners, all in one place, including whole body MRI scans from Prenuvo and adaptive bed systems from Eight Sleep. This is just the beginning of a larger benefits program that will make comprehensive, holistic care more accessible and affordable for subscribers. "True health doesn't happen in a vacuum.

    3/10/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 5:46:12 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cencora Inc.

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    11/14/24 1:22:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Financials

    Live finance-specific insights

    View All

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

    2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025. Financial Results "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true pr

    2/24/26 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care